Human papillomavirus (HPV): college male's knowledge, perceived risk, sources of information, vaccine barriers and communication

Mira L Katz, Janice L Krieger, Anthony J Roberto, Mira L Katz, Janice L Krieger, Anthony J Roberto

Abstract

BACKGROUND: Human papillomavirus (HPV) is a common sexually transmitted infection. With the U.S. Food and Drug Administration (FDA) approval of an indication for the HPV vaccine for males, it is important to assess male college student's HPV knowledge, perceived risk, and sources of information, as well as HPV vaccine barriers and communication. METHODS: This was a cross-sectional survey study of 165 male college students. The participants completed a survey about HPV and the HPV vaccine. RESULTS: Among the 165 participants, most males had poor HPV knowledge, in that 132 (80.0%) reported having had sexual intercourse, but only 20 (12.1%) perceived being at risk for acquiring HPV. Information sources about HPV were commercials/advertisements, friends, news and health education programs. Concern about the HPV vaccine's long-term effects and cost were the most frequently reported barriers. Most students reported having a regular healthcare provider, but had difficulty getting to their provider, and finding time to discuss the HPV vaccine with their provider. Additionally, most students reported relying on their parents when making medical decisions and being willing to discuss the HPV vaccine with their healthcare provider to make an informed decision about the vaccine. CONCLUSIONS: Educational programs providing information about HPV, the HPV vaccine, and communication skills training are needed for male college students, parents, and healthcare providers. Findings from this study will guide the development of HPV vaccine messages and educational programs that should be tested in future research.

References

    1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. J Am Med Assoc. 2007;297:813–19.
    1. Weinstock H, Berman S, Cates W., Jr Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6–10.
    1. Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, National Health and Nutrition Examination Survey, 1999–2004. Sex Transm Dis. 2008;35:357–60.
    1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S3/1–10.
    1. Nielson CM, Flores R, Harris RB, Abrahamsen M, Papenfuss MR, Dunne EF, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev. 2007;16:1107–14.
    1. Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health. 2010;46(4 Suppl):S12–19.
    1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S3/11–25.
    1. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113:3036–46.
    1. American College Health Association. American College Health Association – National College Health Assessment II, Reference Group Executive Summary, Spring 2010. Linthicum, MD: American College Health Association; 2010.
    1. Siegel DM, Klein DI, Roghmann KJ. Sexual behavior, contraception, and risk among college students. J Adolesc Health. 1999;25:336–43.
    1. United States Food and Drug Administration. FDA News Release. Silver Spring, MD: Jun 8, 2006. FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus. Available at: .
    1. United States Food and Drug Administration. FDA News Release. Silver Spring, MD: Sep 12, 2008. FDA Approves Expanded Use for Garasil to Include Preventing Certain Vulvar and Vaginal Cancers. Available at: .
    1. Centers for Disease Control and Prevention (CDC) FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) Morb Mortal Wkly Rep. 2010;59(20):630–2.
    1. United States Food and Drug Administration. FDA News Release. Silver Spring, MD: Oct 16, 2009. FDA Approves New Indication for Gardasil to Prevent Genital Warts in Men and Boys. Available at: .
    1. United States Food and Drug Administration. FDA News Release. Silver Spring, MD: Dec 22, 2010. Gardasil Approved to Prevent Anal Cancer. Available at: .
    1. Daley EM, Marhefka SL, Buhi ER, Vamos CA, Hernandez ND, Giuliano AR. Human papillomavirus vaccine intentions among men participating in a human papillomavirus natural history study versus a comparison sample. Sex Transm Dis. 2010;37:644–52.
    1. Hernandez BY, Wilkens LR, Thompson PJ, Shvetsov YB, Goodman MT, Ning L, et al. Acceptability of prophylactic human papillomavirus vaccination among adult men. Hum Vaccin. 2010;6:467–75.
    1. Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health. 2010;46:113–23.
    1. Reiter PL, Brewer NT, Smith JS. Human papillomavirus knowledge and vaccine acceptability among a national sample of heterosexual men. Sex Transm Infect. 2010;86:241–6.
    1. Witte K, Cameron KA, McKeon JK, Berkowitz JM. Predicting risk behaviors: development and validation of a diagnostic scale. J Health Commun. 1996;1:317–41.
    1. Brewer NT, Ng TW, McRee AL, Reiter PL. Men’s beliefs about HPV-related disease. J Behav Med. 2010;33:274–81.
    1. Ferris DG, Waller JL, Miller J, Patel P, Price GA, Jackson L, et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. J Am Board Fam Med. 2009;22:34–42.
    1. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis. 2009;36:58–62.
    1. Jones M, Cook R. Intent to receive an HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health. 2008;57:23–32.
    1. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis. 2010;37:197–203.
    1. Sandfort JR, Pleasant A. Knowledge, attitudes, and informational behaviors of college students in regard to the human papillomavirus. J Am Coll Health. 2009;58:141–9.
    1. Allen JD, Fantasia HC, Fontenot H, Flaherty S, Santana J. College men’s knowledge, attitudes, and beliefs about the human papillomavirus infection and vaccine. J Adolesc Health. 2009;45:535–7.
    1. Robert AC, Sonenstein FL. Adolescents’ reports of communication with their parents about sexually transmitted diseases and birth control: 1988, 1995, and 2002. J Adolesc Health. 2010;46:532–7.
    1. Aspy CB, Vesely SK, Oman RF, Rodine S, Marshall L, McLeroy K. Parental communication and youth sexual behaviour. J Adolesc. 2007;30:449–66.
    1. Miller KS, Levin ML, Whitaker DJ, Xu X. Patterns of condom use among adolescents: the impact of mother–adolescent communication. Am J Public Health. 1998;88:1542–4.
    1. Cardarelli R, Cardarelli KM. Recommendations for primary care physicians to improve HPV vaccination rates during clinical encounters. Osteopath Med Prim Care. 2008;2:10.
    1. McRee AL, Reiter PL, Chantala K, Brewer NT. Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev. 2010;19:1937–44.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj